RecruitingNot ApplicableNCT07031323

OnTrackCF: Engagement, Feasibility, and Acceptability Study


Sponsor

Boston Children's Hospital

Enrollment

60 participants

Start Date

Nov 20, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Diagnosed with CF
  • 18+ years of age
  • Prescribed a CFTR modulator therapy to be taken twice a day
  • Can speak and read English
  • Have regular access to an iOS or Android tablet or smartphone with internet access.

Exclusion Criteria1

  • \) Any situation, in the opinion of the Investigator, that would compromise the safety of the patient or the quality of the data

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALOnTrackCF

OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.


Locations(3)

University of Alabama-Birmingham

Birmingham, Alabama, United States

Johns Hopkins University

Baltimore, Maryland, United States

Boston Children's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07031323


Related Trials